Panjang
ONTX: Start of Phase 1 trials; very large gap to fill
This stock had 100M volume today-- which is unusual, therefore significant. I did some forensic analysis of their news and it appears that they had a phase 3 survival events failure which means that the meds they were testing did not increase the chances of survival among cancer patients.
Now they start over again (Phase 1) on their other cancer drugs.
I noticed that they tried to push these cancer drugs as potential COVID-19 treatments but nobody bought the news and it appears that the scientific community didn't really see any potential as a treatment.
I don't plan to take any positions in this stock but I am sure that this chart will be of interest to somebody.
Now they start over again (Phase 1) on their other cancer drugs.
I noticed that they tried to push these cancer drugs as potential COVID-19 treatments but nobody bought the news and it appears that the scientific community didn't really see any potential as a treatment.
I don't plan to take any positions in this stock but I am sure that this chart will be of interest to somebody.
Nota
ONTX is currently rated a "BUY" according to my scripts.
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.